key: cord-0025854-gn52ky9u authors: Xiao, Xiao; Zhou, Jun; Fang, Meng; Ji, Jun; Huang, Chenjun; Du, Fei; Ai, Wenchao; Wang, Ying; Gao, Zhiyuang; Qiu, Zhiquan; Gao, Chunfang title: Quantitative detections of TP53 gene mutations improve the diagnosis and prognostic prediction of biliary tract cancers using droplet digital PCR date: 2021-11-23 journal: J Clin Lab Anal DOI: 10.1002/jcla.24103 sha: 7fb0bc527698a9888119361fd624a9d91d49eea7 doc_id: 25854 cord_uid: gn52ky9u OBJECTIVE: Biliary tract cancer (BTC) is a rare malignancy and lack of effective diagnostic and prognostic marker. Here, we aimed to investigate the clinical implication of TP53 mutation detection in BTC using droplet digital PCR (ddPCR). METHODS: TP53 gene (loci p.R175H, p.R248Q, p.R248W, and p.R273H) mutation frequencies of 45 pairs of tumor tissues (TTs) and adjacent normal tissues (ANTTs) were analyzed, respectively, using ddPCR. Meanwhile, the same detections were conducted in plasma cell‐free DNA (cfNDA) of 156 subjects including BTC, disease control (DC), and healthy controls (HC). The logistic regression algorithm was established to identify BTC. The correlations between mutations and clinicopathological features as well as the effects of TP53 mutation frequency on BTC prognosis were assessed. RESULTS: The higher mutation of p.R175H was found in TTs compared with ANTT (p = 0.006). The mutation at p.R273H in cfDNA was also higher in BTC when compared with DC and HC (p < 0.05). The logistic algorithms combining p.R273H mutation demonstrated the higher diagnostic efficacy trend than carbohydrate antigen 19–9 (CA19‐9), carcinoembryonic antigen (CEA), and alpha‐fetoprotein (AFP) in identifying BTC from DC (the area under the curves of the algorithm: 0.845, 95% CI:0.775–0.914). The median overall survival (OS) and progression‐free survival (PFS) were significantly shorter when the BTC patients harboring the p.R273H mutation (OS: p = 0.032; PFS: p = 0.046). CONCLUSION: This study revealed for the first time that the quantitative TP53 mutations using the ddPCR might serve as a potential genetic biomarker for BTC diagnosis and prognosis assessment. Biliary tract cancer (BTC) is anatomically classified as gallbladder carcinoma (GBC), cholangiocarcinoma (CCA), and the ampullary carcinoma. Cholangiocarcinoma includes extrahepatic cholangiocarcinoma (ECC) and intrahepatic cholangiocarcinoma (ICC). 1 Although the incidence rate of BTC is relatively low, BTC is characterized by early lymph node and distant metastases and, therefore, often diagnosed lately when the diseases are already in advanced stages. 2 Up to now, tumor resection is still the main therapeutic option although only a small percentage of patients are eligible and curate without recurrence. 3 BTC is a heterogeneous group of related but distinct diseases with various clinical features and different genetics changes. 4 Characterizations of BTC at the genetic levels are essential for understanding its pathogenesis before exploring new diagnostic and therapeutic options for personalized medicine. 5 Molecular typing of BTC will be promising for early identification and prognosis assessment improving patients' outcome. 6 Molecular diagnostic technology has now been proved to be an important and even essential method for targeted therapy and immunotherapy for precision oncology. 7 The clinical application of molecular detection has become more and more feasible due to the progress of new technology during recent half a century. 8 In particular, digital PCR (dPCR) and next-generation sequencing (NGS) are typical important technologies for liquid biopsy which includes detection of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes in cancer patients. 9,10 Quantitative real-time PCR (qPCR), one of the method of choice for molecular diagnostics, is fundamental in preclinical and clinical research. 11 Recently, the development of dPCR represents an innovative evolution of qPCR that may outperform qPCR in clinical applications. 12 Unlike qPCR, dPCR does not rely on calibration curves for absolute quantification of a DNA target molecule. [13] [14] [15] In addition, dPCR has further exhibited a number of unique advantages over qPCR, including decreased variability and superior sensitivity (<0.1%). 16 The tumor suppressor gene tumor protein p53 (TP53) is one of the most commonly mutated genes in various malignancies. 17 Mutations in TP53 not only disrupt its tumor suppressor function, but also are associated with a worsened prognosis and cause resistance to cancer therapy. 17, 18 In our previous study, we found that the genetic abnormality of TP53 occurred as high as 51.7% in the CCA in a 450 cancer panel exploration using NGS. 19 Therefore, in this study, we conducted a retrospective casecontrol study assessing the clinical implications of quantitative TP53 mutations using the droplet-based dPCR in both tissue and cell-free DNA (cfDNA) in BTC patients aiming to identify the potential genetic biomarkers for BTC diagnosis and prognosis assessment. Exclusion criteria were subjects with (1) incomplete medical data; (2) mixed-type BTC; and (3) no blood or tissue sample available. Calculous cholecystitis as disease control (DCs) in this study was diagnosed when the following criteria is met: (1) clinical manifestations and (2) being diagnosed as calculous cholecystitis by B-ultrasound and X-ray cholecystography. The exclusion criteria were: (1) a history of chronic diseases, such as diabetes and coronary heart disease and (2) gender and age mismatch with BTC. Healthy controls (HCs) were demographic healthy blood donors with routine biochemical tests, no history of biliary diseases, and any malignancies. Peripheral blood specimens were collected at the time of diagnosis before treatment. Meanwhile, tissue specimens [tumor tissue (TT) and adjacent normal tissue (ANTT)] were obtained during the operation. For all subjects, specimens were stored at −80°C until analysis. Relevant demographic and clinical data including patients' age, gender, and pathological results were recorded. All laboratory tests, such as immunological detections of carbohydrate antigen 199 (CA19-9), carcinoembryonic antigen (CEA), and alpha-fetoprotein (AFP) as well as biochemical parameters of liver function, were con- The enrolled patients were followed up every 3 months during the first 2 years after surgery and then every 3-6 months thereafter until cancer-induced death or dropout from our project. Progression-free survival (PFS) was measured from the first day of treatment to the date of first objective or clinical sign, death (whichever came first) or to the date of last follow-up visit for patients censored without progression. Overall survival (OS) was measured from the first day of treatment to the date of death or the last date of the follow-up program. CfDNA was extracted from plasma with an average volume of 600μL using the MagMAXTM cell-free DNA isolation kit (Thermo Co. Ltd.) was used for the accuracy assessment for our ddPCR detection system. The allelic frequency of standard was 100%; we diluted it into 50.00%, 10.00%, 1.00%, and 0.10% with dH 2 O as templates and detected using this ddPCR system, respectively. The clinical characteristics, serum laboratory indexes, and TNM stages of 45 cases of BTC with TTs and matched ANTTs are shown in Table S1 . The mutation frequencies of p.R175H, p.R248Q, p.R248W, and p.R273H in TP53 genes showed no significant differences between TTs and ANTTs, with the exception of p.R175H. Higher mutation of p.R175H (p = 0.006) occurred in TTs ( Figure 2 ). The demographic and clinical information of 156 enrolled subjects including two subgroups of BTC (GBC and ICC) and two subgroups of control (DC and HC) for cfDNA detection are shown in Table S2 . The CA19-9, AFP, CEA, and TBA showed significant differences between BTC and the control group (p < 0.05). The mutation frequencies of loci p.R175H, p.R248Q, p.R248W, and p.R273H of TP53 gene from plasma cfDNA are presented in Figure 3 . We found that the mutations at p. R175H Since among the four loci of TP53, p.R273H was demonstrated as the most significant factors for discrimination BTC and controls (see Figure 3 ), we then constructed the logistic algorithms combining p.R273H mutation and the routine laboratory tests based on step-wise logistic regression. Firstly, Model273-1 (=0.431×p. R273H+0.482×AFP+0.005×CA19-9-1.557) was developed for discriminating BTC from DC (calculous cholecystitis). As shown in Figure 4A and Table 2 CI:0.587-0.801) respectively ( Figure 4C , Table 2 ). Figure 4D ). Similarly, patients with mutant p.R273H showed worse PFS compared to those with wild p.R273H (median PFS: 14.0 vs. 20.0 months, p = 0.046, Figure 4E ). Due to the limited case of BTC enrolled, no further stratification regarding the quantitative p.R273H and survival was analyzed. BTC is a rare malignancy often identified at an advanced stage and has extremely poor prognoses. The classification of BTC is complex, and the biological characteristics of each subtype are heterogeneous; therefore, the early diagnosis of the disease is full of challenges. 20 Most patients are diagnosed at advanced stage when treatment is limited to palliative chemotherapy. 21 There are limited options regarding systemic therapy for this disease and historically only multi-agent chemotherapy regimens achieve meaningful responses, but the treatment effect is not satisfied. 22 At present, effective treatment of BTC is in its pacing stage, while genomic profiling of BTC has gradually becoming a reality which allows a better understanding of its biological characteristics and potential new therapeutic targets. 23 Compared with histopathological tumor tissue analysis, liquid biopsy has already shown more advantages in deciphering a full picture of the patient's genomic, such as overcoming the heterogeneity of the tumor and reducing the disadvantages of the invasive sampling and sample error. 24 Digital PCR is one of the most important molecular detection methods in liquid biopsy since dPCR is an accurate nucleic acid quantification method with single-molecule sensitivity. The simplification and visualization of the operation workflow as well as the compatibility of the instrument of ddPCR have greatly accelerated its application in clinical diagnostics. 25 Our research in BTC tissues found that the mutation frequency of p.R175H was significantly higher in TT than in ANTT ( Figure 2) Mounting evidences indicate that the hotspot mutation like p53-R273H promotes cell migration, invasion in vitro, and tumor metastasis in vivo. 34 In addition to this pathogenesis of mutant p.R273H, our experiments had further indicated for the first time that p.R273H might be also useful in clinical diagnosis. In order to make differentiation between BTC and the benign biliary tract disease-calculous cholecystitis, three diagnostic models, Model273-1 for identifying BTC, Model273-2 for GBC, and Model273-3 for ICC, were constructed integrating TP53 mutation and routine tumor maker based on logistic regression. As a result, the logistic algorithm separated BTC from the DC subjects with higher performance than CA19-9, CEA, and AFP did (AUC 0.845 vs 0.786, 0.751 and 0.692, Figure 4) . In F I G U R E 3 Comparison of the TP53 mutation frequencies in cfDNA between BTCs and control groups. Quantitative TP53 mutation detection in plasma cfDNA was measured using ddPCR. TC was used as the control group to compare the differences in mutation frequencies of all four loci (p.R175H, p.R248Q, p.R248W, and p.R273H) of TP53 gene in each experimental group (GBC, ICC, and BTC). The X-axis represents various groups, and the Y-axis represents the mutation frequency of each loci. The mutation frequencies in GBCs and BTCs at p.R175H were higher than that in TC (p < 0.05). Meanwhile, the mutation frequencies in different experimental group (GBC, ICC, and BTC) at p.R273H were higher than that in TC (p < 0.05). GBC, gallbladder cancer; ICC, intrahepatic cholangiocarcinoma; BTC, biliary tract tumor (GBC +ICC); DC, disease control group; and TC, total control group. The significant differences were marked with * for p < 0.05; ** for p < 0.01 Note: Patients were classified according to the positivity of mutations, and then comparisons were made between negative and positive subgroups on the stages of TNM and the number of tumors. TNM, tumor node metastases. The significant differences were marked with * for p < 0.05. In the present study, TP53 mutations at p.R175H, p.R248Q, p.R248W, and p.R273H were stably detected at a prevalence as low as 0.01% using the QX200 ddPCR system. To evaluate the stability of the quantitation using ddPCR, we used the commercial TP53 p.R175H/p.R273H reference standard to verify the precision of the detection. The results showed that the within-run coefficient of variation (CV) was 1.2%-11.37% (see Table S4 ). Furthermore, the between-run CV was 8.87%-9.23% when the standard was diluted into 1% (see Table S5 ). The liquid biopsy using dPCR in this study was not affected by the calibration curve, exhibiting decreased variability, superior day-to-day reproducibility, and sensitivity. 35 Table S2 ). The TP53 mutation (D-E) Kaplan-Meier curves showed that there were significant differences between with (green) and without (gray) p.R273H mutation in the OS and PFS (p < 0.01), indicating that BTC patients with p.R273H mutation suffer a poorer prognosis than those without. WT, wild type; MT, mutated type rate of our study was higher than those from COSMIC study since We would like to thank Dr. Xing Gu and Ms. Minfan Xu for their kind assistance in tissue and blood sample collection. All authors claim that there is no conflict of interest including a desire for financial gain, prominence, professional advancement, or a successful outcome. All authors have accepted responsibility for the entire content of this study and approved its submission. The study was approved by the Institutional Review Boards at the leading study center (EHBHKY2020-02-012). Informed consent was obtained from all individuals included in this study. The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request. Xiao Xiao https://orcid.org/0000-0002-9260-4519 Chunfang Gao https://orcid.org/0000-0002-4891-2944 TA B L E 2 Diagnostic performances of the three p.R273H-based logistic regression models and CA19-9, CEA, and AFP Promising molecular targets for the targeted therapy of biliary tract cancers: an overview Biliary tract cancer prognostic and predictive genomics Novel biomarkers for the diagnosis and prognosis of gallbladder cancer Biliary tract cancers: molecular heterogeneity and new treatment options Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker Molecular genetics and targeted therapeutics in biliary tract carcinoma Targeted therapy and checkpoint immunotherapy in lung cancer Somatic mutations and immune checkpoint biomarkers The evolution of molecular diagnosis using digital polymerase chain reaction to detect cancer via cell-free DNA and circulating tumor cells Recent advances in liquid biopsy in precision oncology research A Quarter century of PCR-applied techniques and their still-increasing fields of use Advances in digital polymerase chain reaction (dPCR) and its emerging biomedical applications ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens Digital PCR: a reliable tool for analyzing and monitoring hematologic malignancies Droplet digital polymerase chain reaction (ddPCR) for the detection of Plasmodium knowlesi and Plasmodium vivax Regulators of oncogenic mutant TP53 gain of function A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials Biliary tract cancer: state of the art and potential role of DNA damage repair Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma) New developments in systemic therapy for advanced biliary tract cancer Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples Portable integrated digital PCR system for the point-of-care quantification of BK virus from urine samples Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma TP53 gain-of-function mutations in circulating tumor DNA in men with metastatic castration-resistant prostate cancer Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract Mutant TP53 G245C and R273H promote cellular malignancy in esophageal squamous cell carcinoma Different TP53 mutations are associated with specific chromosomal rearrangements, telomere length changes, and remodeling of the nuclear architecture of telomeres Common cancer mutations R175H and R273H drive the p53 DNA-binding domain towards aggregation-prone conformations p53-R273H upregulates neuropilin-2 to promote cell mobility and tumor metastasis Absolute quantification by droplet digital PCR versus analog real-time PCR Comparison of digital PCR platforms and semi-nested qPCR as a tool to determine the size of the HIV reservoir Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA Evaluation of EGFR mutations in NSCLC with highly sensitive droplet digital PCR assays Targeting P53 as a future strategy to overcome gemcitabine resistance in biliary tract cancers Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway Additional supporting information may be found in the online version of the article at the publisher's website.